The company’s portfolio includes several approved biosimilars, such as SB2 (infliximab), SB4 (etanercept), and SB5 (adalimumab) for autoimmune diseases. In oncology, products like SB3 (trastuzumab) and SB8 (bevacizumab) provide options for cancer treatment. Additionally, SB11 (ranibizumab) and SB15 (aflibercept) target retinal disorders, enhancing affordability in ophthalmology care.
Samsung Bioepis collaborates with global partners, including Biogen and Organon, to expand its biosimilars' reach across major markets in North America, Europe, and Asia.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze